TAO Synergies Inc.
TAOXNasdaq
$3.46
↓ -2.3%Jul 17 close · end-of-day
Price
1Y↓ -62.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$26.6M
Enterprise Value
$23.0M
P/E
—
P/S
—
P/B
1.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$24.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-106.9%
ROIC
-37.4%
Debt / Equity
—
Net Cash
$3.6M
Return 1Y
-63.2%
Company profile
Synaptogenix, Inc. focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
- CEO
- Alan J. Tuchman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Headquarters
- New York
- Website
- synaptogen.com
Management & directors
- Silverman JoshuaExecutive Chairman
- Weinstein RobertChief Financial Officer
- Tuchman Alan JChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
TAOX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$388,774.00—
Diluted EPS$0.43↑ +975.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2020 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0.00 | $299,061.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | -$6.8M | -$9.0M |
| Net income | -$11.2M | -$11.2M | -$12.7M | -$12.6M | -$5.6M | -$6.0M | -$12.8M | -$28.7M |
| Diluted EPS | — | — | $12.03 | $2.51 | -$0.81 | $29.56 | -$10.99 | -$8.81 |
| Operating cash flow | — | — | -$8.1M | -$8.7M | -$11.2M | -$5.2M | -$4.9M | -$6.4M |
| Free cash flow | — | — | -$8.1M | -$8.7M | -$11.2M | -$5.2M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -3025.2% |
| Net margin | — | — | — | — | — | — | — | -9609.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $3,962.00 | $203,371.00 | — | $388,774.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.6M | -$2.0M | — | -$1.1M | -$3.0M | -$1.8M | -$3.1M | -$1.3M |
| Net income | -$1.3M | -$5.7M | -$5.5M | $385,169.00 | -$17.5M | -$3.9M | -$7.7M | $4.3M |
| Diluted EPS | -$1.18 | -$5.01 | -$4.39 | $0.04 | -$11.26 | -$1.56 | $3.97 | $0.43 |
| Operating cash flow | -$853,534.00 | -$1.0M | -$1.2M | -$2.0M | -$749,072.00 | -$1.2M | -$2.5M | -$1.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -76623.8% | -884.8% | — | -339.0% |
| Net margin | — | — | — | — | -442101.9% | -1929.1% | — | 1094.3% |
Company news
Apr 4, 2026
Oct 10, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-17 | Silverman Joshua· Executive Chairman | Tax withholding | 40,000 | $7.23 | $289,200.00 | filing |
| 2025-10-17 | Bernstein Bruce | Tax withholding | 10,000 | $7.23 | $72,300.00 | filing |
| 2025-10-17 | Singer William S. | Tax withholding | 6,000 | $7.23 | $43,380.00 | filing |
| 2025-10-17 | WEINSTEIN ROBERT· Chief Financial Officer | Tax withholding | 4,000 | $7.23 | $28,920.00 | filing |
| 2025-10-17 | Ephron Robert | Tax withholding | 3,000 | $7.23 | $21,690.00 | filing |
| 2025-10-17 | Ephron Robert | Award | 7,500 | $0.00 | $0.00 | filing |
| 2025-10-17 | Singer William S. | Award | 15,000 | $0.00 | $0.00 | filing |
| 2025-10-17 | Silverman Joshua· Executive Chairman | Award | 100,000 | $0.00 | $0.00 | filing |
| 2025-10-17 | Bernstein Bruce | Award | 25,000 | $0.00 | $0.00 | filing |
| 2025-10-17 | WEINSTEIN ROBERT· Chief Financial Officer | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-06-30 | Silverman Joshua· Executive Chairman | Tax withholding | 16,768 | $7.85 | $131,628.80 | filing |
| 2025-06-30 | Bernstein Bruce | Tax withholding | 9,863 | $7.85 | $77,424.55 | filing |
| 2025-06-30 | SCHECHTER JONATHAN | Tax withholding | 8,630 | $7.85 | $67,745.50 | filing |
| 2025-06-30 | Singer William S. | Tax withholding | 6,164 | $7.85 | $48,387.40 | filing |
| 2025-06-30 | WEINSTEIN ROBERT· Chief Financial Officer | Tax withholding | 6,164 | $7.85 | $48,387.40 | filing |
| 2025-06-30 | TUCHMAN ALAN J· Chief Medical Officer | Tax withholding | 1,726 | $7.85 | $13,549.10 | filing |
| 2025-06-30 | SCHECHTER JONATHAN | Award | 21,575 | $0.00 | $0.00 | filing |
| 2025-06-30 | WEINSTEIN ROBERT· Chief Financial Officer | Award | 15,410 | $0.00 | $0.00 | filing |
| 2025-06-30 | Silverman Joshua· Executive Chairman | Award | 41,919 | $0.00 | $0.00 | filing |
| 2025-06-30 | Singer William S. | Award | 15,410 | $0.00 | $0.00 | filing |
| 2025-06-30 | TUCHMAN ALAN J· Chief Medical Officer | Award | 4,315 | $0.00 | $0.00 | filing |
| 2025-06-30 | Bernstein Bruce | Award | 24,657 | $0.00 | $0.00 | filing |
Latest 22 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.